Practice Guidelines in Oncology for Rectal Cancer recommendations for the management of potentially resectable synchronous metastatic disease Describe the role of chemotherapy with bevacizumab in the conversion of CRLM to resectable status Case
Search Results
Synchronous Metastatic Rectal Cancer Completely Resected After Multidisciplinary Planning and Treatment: A Case Report
Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong
NCCN News
or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab. The following parameters were added for reporting of pathologic stage: lymphovascular invasion, perineural invasion, and extra nodal tumor
Treatment of Metastatic Pancreatic Cancer
Andrew H. Ko and Margaret A. Tempero
: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary
Arantzazu Barquín García, Sara Palacios-Zambrano, Felipe Lozano Alarcón, Beatriz Paumard-Hernández, Miguel Quiralte Pulido, Paloma Navarro, Laura Rodríguez, Isabel Salas Villar, and Jesús García-Donas
200). These findings led to the case being reclassified as a recurrence of the cervical adenocarcinoma that had been diagnosed and treated 23 years earlier. Based on the new results, bevacizumab was prescribed at a dose of 15 mg/kg every 21 days
Therapy of Adenocarcinoma of Unknown Primary: Are We Making Progress?
F. Anthony Greco
cancer of unknown primary: from autopsy to microarray . Eur J Cancer 2007 ; 43 : 2026 – 2036 . 3. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J
A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang
hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large
Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine
New Treatments for Renal Cell Carcinoma: Targeted Therapies
Philip J. Saylor and M. Dror Michaelson
trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med 2003 ; 349 : 427 – 434 . 7 Yang JC Sherry RM Steinberg SM . Randomized study of high-dose and low-dose interleukin-2 in
Machine Learning–Based Early Warning Systems for Acute Care Utilization During Systemic Therapy for Cancer
Robert C. Grant, Jiang Chen He, Ferhana Khan, Ning Liu, Sho Podolsky, Yosuf Kaliwal, Melanie Powis, Faiyaz Notta, Kelvin K.W. Chan, Marzyeh Ghassemi, Steven Gallinger, and Monika K. Krzyzanowska
) Sensitivity at the 35% risk threshold. Abbreviations: AUROC, area under the receiver operating characteristic curve; Bev, bevacizumab; FOLFIRI, leucovorin/5-FU/irinotecan; mFOLFOX6, modified continuous-infusion 5-FU/leucovorin/oxaliplatin; PPV, positive
Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer
Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque
categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic
